Home About Us Management Product Pipeline Collaborators Contact Us


Pipeline


Candidate & Indication
Developmental Stage
Pre-clinical
Toxicology
Phase 1
Phase 2
PLAP; injection formulation to enhance cancer treatments, and reduce muscle wasting and cachexia in cachectic cancer patients
Exit after Phase 1 or Phase 2 trial
PLAP; oral formulation to treat metabolic syndrome and or Muscle Wasting in obese/type 2 diabetic patients
Exit after Phase 1 or Phase 2 trial
Topical PLAP with mesenchymal stem cells to promote diabetic wound healing
Develop fully